Home > Riviste > European Journal of Physical and Rehabilitation Medicine > Fascicoli precedenti > European Journal of Physical and Rehabilitation Medicine 2010 September;46(3) > European Journal of Physical and Rehabilitation Medicine 2010 September;46(3):401-10

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE

Rivista di Medicina Fisica e Riabilitativa dopo Eventi Patologici


Official Journal of the Italian Society of Physical and Rehabilitation Medicine (SIMFER), European Society of Physical and Rehabilitation Medicine (ESPRM), European Union of Medical Specialists - Physical and Rehabilitation Medicine Section (UEMS-PRM), Mediterranean Forum of Physical and Rehabilitation Medicine (MFPRM), Hellenic Society of Physical and Rehabilitation Medicine (EEFIAP)
In association with International Society of Physical and Rehabilitation Medicine (ISPRM)
Indexed/Abstracted in: CINAHL, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,063


eTOC

 

ADVANCES IN THE MANAGEMENT OF SPASTICITY  


European Journal of Physical and Rehabilitation Medicine 2010 September;46(3):401-10

lingua: Inglese

Managing spasticity with drugs

Simon O., Yelnik A. P.

1 Physical Medicine and Rehabilitation Department, AP-HP, GH Bichat, University Paris7, Paris, France
2 Physical Medicine and Rehabilitation Department, AP-HP, G.H. Lariboisière-F.Widal, University Paris7, Paris, France


FULL TEXT  


Spasticity is a common symptom observed after pyramidal system lesion. The treatment of spasticity has considerably changed during last years, notably with the generalization of Botulinum toxin use. However, the treatment of spasticity should consider all therapeutic possibility in accordance with patient status and objective. Drugs are only a part of the treatment and physical therapy must always be used. Others treatments such as surgery, orthosis, occupational therapy must also be discussed individually. Several guidelines are now available for Botulinum toxin treatment but only the French guidelines consider all drug therapies. This review addresses the different drugs commonly used on the basis of an extensive review of literature. Some facts are clearly established by randomized controlled trials but a certain number of questions remains unclear and only clinical experience and consensus can guide injectors.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

olivier.simon@bch.aphp.fr